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Abstract
Background: Fragile X syndrome (FXS) is the most common form of inherited intellectual disability, resulting from the
loss of function of the fragile X mental retardation 1 (FMR1) gene. The molecular pathways associated with FMR1
epigenetic silencing are still elusive, and their characterization may enhance the discovery of novel therapeutic targets as
well as the development of novel clinical biomarkers for disease status.
Results: We have deployed customized epigenomic profiling assays to comprehensively map the FMR1 locus chromatin
landscape in peripheral mononuclear blood cells (PBMCs) from eight FXS patients and in fibroblast cell lines derived from
three FXS patient. Deoxyribonucleic acid (DNA) methylation (5-methylcytosine (5mC)) and hydroxymethylation (5-
hydroxymethylcytosine (5hmC)) profiling using methylated DNA immunoprecipitation (MeDIP) combined with a custom
FMR1 microarray identifies novel regions of DNA (hydroxy)methylation changes within the FMR1 gene body as well as in
proximal flanking regions. At the region surrounding the FMR1 transcriptional start sites, increased levels of 5mC were
associated to reciprocal changes in 5hmC, representing a novel molecular feature of FXS disease. Locus-specific validation
of FMR1 5mC and 5hmC changes highlighted inter-individual differences that may account for the expected DNA
methylation mosaicism observed at the FMR1 locus in FXS patients. Chromatin immunoprecipitation (ChIP) profiling of
FMR1 histone modifications, together with 5mC/5hmC and gene expression analyses, support a functional relationship
between 5hmC levels and FMR1 transcriptional activation and reveal cell-type specific differences in FMR1 epigenetic
regulation. Furthermore, whilst 5mC FMR1 levels positively correlated with FXS disease severity (clinical scores of aberrant
behavior), our data reveal for the first time an inverse correlation between 5hmC FMR1 levels and FXS disease severity.
Conclusions: We identify novel, cell-type specific, regions of FMR1 epigenetic changes in FXS patient cells, providing new
insights into the molecular mechanisms of FXS. We propose that the combined measurement of 5mC and 5hmC at
selected regions of the FMR1 locus may significantly enhance FXS clinical diagnostics and patient stratification.
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Background
Fragile X syndrome (FXS) is the most common inherited
form of mental retardation and autism in males [1, 2]. The
syndrome is commonly associated with the expansion of
cytosine-guanine-guanine (CGG) trinucleotide repeats in
the 5′ untranslated region (5′UTR) of the human fragile X
mental retardation 1 (FMR1) gene. In patients with more
than 200 CGG repeats, the aberrant, CGG-repeat expanded
FMR1 messenger ribonucleic acid (mRNA) mediates FMR1
gene silencing [3] resulting in the absence of fragile X men-
tal retardation protein (FMRP) expression, a translational
regulator involved in neurotransmitter mediated synaptic
maturation and plasticity [2]. Premutation carriers of FXS
display a varying number of CGG repeats (55–200) associ-
ated with either normal or mild deficits in the expression of
the FMR1 gene [4, 5]. Despite two decades of studying the
(epi)genetic dynamics of the FMR1 locus, little is known
about the molecular events and pathways that lead to
FMR1 silencing in individuals carrying a full-mutated (>200
CGG repeats) allele. Aberrant deoxyribonucleic acid (DNA)
hypermethylation of the FMR1 promoter CpG island and
CGG repeats is strongly associated with FMR1 gene silen-
cing and represents a molecular hallmark of full-mutation
FXS patients [6–11]. The acquisition of DNA methylation
at the FMR1 CpG island is accompanied by hypoacetylation
of associated histones and acquisition of repressive histone
post-translational modifications such as the methylation of
the lysine 9 of histone H3 (H3K9me) and chromatin con-
densation, all characteristics of a transcriptionally inactive
gene [12–15]. The methylation status of FMR1 in full-
mutation patients can vary across cell types (methylation
mosaicism) and is significantly associated with the clinical
phenotype of FXS patients [5, 16–20]. The methylation ob-
served at the FMR1 CpG island extends beyond the FMR1
promoter and spreads into the first intron [21, 22]. A small
number of full-mutation, unmethylated individuals have
also been reported [23]. These patients displayed a FMR1
promoter epigenetic pattern comparable to that of normal
controls, in accordance with normal transcription levels
and consistent with a euchromatic configuration. The
mechanisms preventing the initial methylation and protect-
ing against a repressive chromatin configuration are un-
known, and their identification may help understand the
key pathways affected in the majority of full-mutation pa-
tients and might ultimately lead to new therapeutic oppor-
tunities for restoring normal FMR1 expression levels in
FXS patients [12, 24].
DNA hydroxymethylation (5-hydroxymethylcytosine
(5hmC)), a DNA methylation (5-methylcytosine (5mC))
derivative was rediscovered in mouse Purkinje cells and
granule neurons [25, 26]. These newly characterized epi-
genetic marks are catalyzed by a group of enzymes be-
longing to the ten-eleven translocation methylcytosine
dioxygenase (TET) family (TET 1, 2, and 3) [27]. The
5hmC mark is distributed over the promoter and bodies
of transcriptionally active genes as well as enhancer ele-
ments [28–30] and may both represent an epigenetic
modification in its own right and also an intermediate
product in an active DNA demethylation pathway, ac-
counting for the maintenance of DNA demethylation at
CpG-rich promoters [27, 31]. 5hmC is particularly
enriched in the central nervous system where it may
play specific and dynamic functions in the regulation of
gene expression [32] including regulation of alternative
splicing as well as synaptic function in the brain [33].
The distribution of 5hmC is dynamically regulated dur-
ing neurodevelopment, it may play a role in a number of
neurodegenerative diseases [34, 35] and is also perturbed
in an animal model of Rett syndrome, a neurodevelop-
mental disorder caused by a mutation in the MeCP2
gene which encodes a 5mC and a 5hmC binding protein
which targets transcriptional activation or repression
functions to its binding sites [32, 36, 37].
In the present study, we have used broad epigenomic
profiling of the FMR1 locus (beyond the well-characterized
promoter/CpG island regions) to identify novel epigenetic
marks and mechanisms that may contribute to FMR1 silen-
cing in blood-derived FXS full-mutation patients samples.
We have integrated FMR1 locus-specific methylation (5mC
and 5hmC), histone post-translational modifications, and
gene expression with clinical scores of aberrant behavior in
a group of eight FXS patients. Our data reveal novel
molecular-clinical phenotype associations that may provide
novel diagnostic tools for the prediction and stratification
of FXS disease severity.
Results
(hydroxy)-MeDIP profiling identifies novel regions of 5mC
and 5hmC changes in the FMR1 locus of FXS patient
blood samples
(hydroxy-)methylated DNA immunoprecipitation assays,
(h)MeDIP, were used to investigate the DNA methylation
(5mC) and hydroxymethylation (5hmC) landscape of the
broader FMR1 locus in peripheral blood mononuclear
cells (PBMC) samples from eight fragile X syndrome pa-
tient and four control individual samples (Fig. 1a). The
age, ABC clinical score, FMR1 CGG repeat size, and
FMR1 expression for each patient are indicated in Add-
itional file 1: Table S1, alongside locus specific measure-
ment for each epigenetic mark investigated in this study.
Input and (h)MeDIP-enriched fractions were labeled and
applied onto a custom designed array covering the entire
FMR1 genomic region on chromosome X (hg19, ChrX:
146,911,760–147,159,387: summarized in the “Methods”
section).
Analyses of the 5mC profile using a genome vi-
sualization tool detected the expected DNA hypermethy-
lation at an estimated 3.8-kb-long region surrounding
Brasa et al. Clinical Epigenetics  (2016) 8:15 Page 2 of 15
the transcriptional start site of FMR1 in FXS PBMC
(region II covering −3.5 kb/+0.3 kb of the FMR1 start
site, ChrX: 146,990,000–146,993,800) (Fig. 1c, Table 1).
An additional region of DNA hypermethylation was
an apparent downstream of FMR1 coding region (re-
gion V). These signatures are observed by MeDIP
array across all individual PBMC samples (Fig. 1c,
Table 1) and identify novel regions of DNA methyla-
tion perturbation in FXS patient samples.
The profiling of hydroxymethylated DNA in PBMC sam-
ples revealed broad 5hmC perturbations in FXS patient
samples. Hydroxymethylated CpGs are typically found at
transcribed gene bodies, active enhancers, and at a limited
cohort of annotated transcriptional start site (TSS) [28–30].
Interestingly, our analyses revealed 5hmC enrichment
in control over FXS samples within four FMR1 locus
genomic regions located (1) upstream of FMR1, (2) at
the TSS, (3) throughout the first intron, and (4) in a
region located between introns 13 and 16 (Fig. 1c,
Table 1), highlighting FMR1 hypo-hydroxymethylation as
a novel features of fragile X syndrome. To validate the
specificity of FMR1 DNA (hydroxy)methylation perturba-
tions, additional control genomic regions were investi-
gated from the array data and validated by (h)MeDIP-PCR
and did not display differential 5mC/5hmC distribution
or enrichment in healthy controls and FXS samples
(Fig. 1b, Additional file 2: Figure S1C and Additional
file 3: Figure S2C).
Fig. 1 FMR1 locus (h)MeDIP profiling identifies novel regions of 5mC and 5hmC changes in FXS patient PBMC samples. a. Experimental overview.
Methylated DNA immunoprecipitation (MeDIP) assay was used to profile DNA methylation (5mC), DNA hydroxymethylation (5hmC). Chromatin
immunoprecipitation (ChIP) was used to profile histone post-translational modifications (PTM). Antibody (Ab) b–c. The graphs illustrate the relative
enrichment of the indicated mark (log2 fold enrichment) in FXS (red) and control (blue) PBMCs. The upper panel illustrates the chromosomal and
genomic location locations as well as the indicated referenced Refseq genes: FMR1, and referenced antisense non coding RNAs (FMR1AS1 and
L29074.3). This snapshot illustrates the epigenetic landscape over a region covering 79 kb on ChrX: 146971000-147050000 (c). RPL19 and GAPDH
provide controls regions of no changes in 5mC and 5hmC (b). In the graphs, the thicker lines indicate higher deviation between biological repli-
cates (controls n = 4; FXS n = 8) (aggregation mean, sliding window 529 bp). Regions I to V were selected as regions of strongest apparent epi-
genetic variation across epigenetic marks and cell types based on epigenomic landscape visualization illustrated in Figs. 1 and 3. The
chromosome coordinates of these regions are provided in Table 1
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Overall, our analyses identify novel regions of 5mC
changes along FMR1 and beyond the regions already de-
scribed outside of the promoter/first intron regions [21].
Our data also describe for the first time broad changes
in FMR1 5hmC levels and distribution in FXS PBMCs,
highlighting novel molecular features that may be associ-
ated with FMR1 epigenetic regulation in fragile X syn-
drome patient cells.
Inter-individual variations in FMR1 5mC and 5hmC
changes in FXS PBMC
Next, we developed novel locus-specific (h)MeDIP-PCR
assays based on the identification of novel regions of
(hydroxy)methylation (5mC and 5hmC) changes in FXS
PBMC-derived DNA samples. Our results (Fig. 2a) con-
firmed significant increase of 5mC levels at proximity of
FMR1 TSS. Further discrete 5mC perturbations are ob-
served in the FMR1 gene body with moderate decrease in
5mC levels within the alternative-splicing rich region (re-
gion IV, detected with 3F9G1 assay) spanning FMR1 exon
15 [36, 37], and a moderate increase 10kbp downstream
of the FMR1 3′UTR (region V, detected with assay 3H7-
8). On the other hand, 5hmC was significantly decreased
throughout the FMR1 locus with broader changes taking
place at the promoter region and through the entire
FMR1 first intron, validating in a semi-quantitative, inde-
pendent manner the array-based identification of novel re-
gions of FMR1 5mC and 5hmC changes in FXS PBMCs.
Interestingly, PCR validation highlighted important inter-
individual variations in 5hmC levels across FXS patient
samples in most interrogated regions, representing poten-
tial inter-individual differences in FMR1 epigenetic regula-
tion and/or highlighting FMR1 genetic/transcriptional
mosaicism in a population of FXS patient PBMCs (Add-
itional file 2: Figure S1 and Additional file 3: Figure S2).
The comparison of 5mC and 5hmC MeDIP-array data
from individual patients (Fig. 2b) to locus specific 5mC
(MeDIP-PCR and pyrosequencing) and 5hmC (hMeDIP-
PCR) (Fig. 2a, c) reveals consistent patterns of 5mC/5hmC
levels at the TSS region where 5mC/5hmC changes are
most evident. Amongst the analyzed FXS samples, sam-
ples from patients B and E (arrowed) show healthy control
levels of 5hmC while samples from patients C and F dis-
play the strongest reduction in 5hmC, both with array-
and PCR-based readouts. Interestingly, these two patients
are also characterized by mosaic CGG repeat, the highest
FMR1 expression levels, and the lowest reported clinical
scores (Additional file 1: Table S1) highlighting the correl-
ation between molecular and phenotypic data (see Fig. 5).
Importantly, the comparison of 5mC and 5hmC points to
anti-correlation between the two epigenetic marks (Fig. 2a,
c, arrows). Our data highlight broad 5hmC level changes
across the FMR1 locus of FXS patients PBMCs together
with reciprocal 5mC/5hmC changes at the FMR1 TSS re-
gion suggesting that combined measurement of 5mC and
5hmC may provide enhanced molecular and functional
characterization of FXS patient samples.
Changes in 5mC and 5hmC associate with broad changes
in the FMR1 locus histone post-translational modification
landscape in FXS patients
To further investigate the molecular features underlying
FMR1 silencing in FXS and select markers of interest to be
evaluated in clinical FXS PBMC samples, we carried out
chromatin immunoprecipitation (ChIP) using antibodies
for histone post-translational modifications (PTM) associ-
ated to gene repression (H3K27me3, H3K9me2, H3K9me3)
and gene activation (H3K36me3, H3K4me2, H3K9ac,
H4K16ac, H4K20me1) on chromatin from three FXS fibro-
blasts lines (Coriell GM05848 fibroblasts from a 4-year-old
patient, GM07072 fetal lung fibroblasts from 22-week-old
fetus, and GM09497 fibroblasts from a 28-year-old FXS
Table 1 Chromosomal coordinates of regions of FMR1 epigenetic variability in FXS cells. The major regions or FMR1 epigenetic
changes identified in FXS PBMCs and fibroblasts (Figs. 1 and 3). Each region is indicated with a unique ID. The functional location
(relative to the transcriptional start site (TSS)/untranslated regions (UTR)), chromosome coordinates, and estimated size of the region
of perturbation are indicated
Region ID Functional genomic location Chromosome coordinates Size (kb)
Region I Upstream—L29074.3 ChrX: 146981500-146986000 4.5
TSS −12 kb/−7.5 kb
Region II Promoter—intron1 ChrX: 146990000-146993800 3.8
TSS −3.5 kb/+0.3 kb
Region III Intron1 ChrX: 146993800-147004000 9.9
TSS +0.3 kb/+10.2 kb
Region IV Gene body—introns 12–16 ChrX: 147018000-147028000 10
TSS +24.5 kb/34.5 kb
Region V Downstream ChrX: 147038000-147048000 10
3′UTR +6.1 kb/+15.3 kb
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Fig. 2 (See legend on next page.)
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patient) and one healthy control neonatal fibroblast cell line
(BJ1) (Fig. 3). 5mC and 5hmC (h)MeDIP assays were also
deployed to compare chromatin changes to methylation
perturbations along the FMR1 locus. (h)MeDIP and ChIP
inputs and IP-enriched fractions were labeled and applied
onto the custom-designed FMR1 microarray. Our data
highlight extensive epigenetic remodeling across the FMR1
locus, with most significant changes taking place within re-
gions I to V identified by (h)MeDIP in FXS PBMCs (Fig. 3).
Although we cannot formally exclude that discrete regions
of epigenetic changes may be related to the tissue origin
and clinical background (including age) of patients, these
results overall corroborate the idea that the newly identified
regions correspond to bona-fide FMR1 regulatory elements
perturbed in FXS samples and potentially implicated in mo-
lecular mechanisms associated to its silencing in target
cells. In particular, in region II, which encompasses a region
surrounding the TSS, the DNA hypermethylation was
found associated with extensive change in most of the
assayed marks, including decreased H3K9me2 (loss of
boundary region), decreased active marks (H3K4me2,
H3K9ac, H4K16ac, H4K20me1), and massive enrichment
for the constitutive heterochromatin marks H3K9me3 and
H4K20me3. No apparent change in H3K27me3 was de-
tected at the TSS. Broad epigenetic landscape changes were
also detected within FMR1 gene body; some marks chan-
ged throughout the gene body (e.g., H3K36me3), with most
changes detected at the level of the first intron (region III)
and between introns 14 and 15 (within region IV). Overall,
this configuration represents a local epigenetic switch from
euchromatin to heterochromatin, consistent with transcrip-
tional gene repression. Contrary to the TSS, we found de-
creased methylation (5mC) in intragenic regions III and IV.
Elevated gene body DNA methylation was previously re-
ported to prevent spurious transcription within the gene
body of active genes [38]. Loss of intragenic DNA methyla-
tion is thus consistent with FMR1 epigenetic silencing. In
contrast to FXS PBMCs, no apparent change in 5hmC (low
both in control and FXS cells) was observed in the gene
body in FXS fibroblasts, suggesting cell-type (and
transcriptional state)-specific differences in the distribution
and levels of this mark. Finally, epigenetic perturbations
were observed in regions upstream and downstream of
FMR1 coding region (region I and region V, respectively)
highlighting potential novel FMR1 regulatory regions.
To validate the microarray-based epigenetic landscape
data obtained by ChIP-array, quantitative polymerase
chain reaction (qPCR) assays were run over the region
surrounding the TSS using ChIP and input material used
for arrays. The results, illustrated in Additional file 4:
Figure S3 confirm reduced enrichment for active marks
(H3K4me2, H3K9ac, H4K16ac) throughout the TSS re-
gion and show increased association of several repressive
marks (H4K20me1, H4K20me3, H3K9me3), overall re-
capitulating array-based data.
To further investigate epigenetic changes and path-
ways associated with FMR1 silencing in FXS PBMCs,
and based on Coriell fibroblast ChIP-array data, native-
ChIP assays using antibodies for histone PTMs, associ-
ated with and contributing to transcriptional gene re-
pression (H3K9me2, H3K9me3) and gene activation
(H3K4me2, H4K20me1), were carried out on fraction-
ated chromatin from eight clinical FXS and three control
PBMC samples. ChIP-enriched and input fractions were
profiled by qPCR using assays designed at FMR1 gen-
omic regions displaying epigenetic changes in FXS fibro-
blasts and PBMCs (Fig. 4). Consistent with FXS
fibroblast ChIP-array data, we found extensive epigenetic
remodeling of H3K4me2 at regions II and III and of
H3K9me3 and H4K20me1 largely encompassing the
FMR1 coding region. Regions outside the FMR1 coding
region were also perturbed at the chromatin level,
highlighting epigenetic changes that may account for
regulatory or structurally important regions for the regu-
lation of the FMR1 locus. A selection of control genomic
loci (RPL19, CDX2, OCT4) did not display changes in
the enrichment of any of the marks tested in FXS cells
(Additional file 5: Figure S4). Overall, our data reveal a
FMR1 locus-wide repressive epigenetic switch and high-
light unprecedented epigenetic marks and pathways that
(See figure on previous page.)
Fig. 2 Inter-individual variation in 5mC and 5hmC levels across the FMR1 locus of FXS patient PBMC samples. a Selected FMR1 genomic regions
of methylation change (Table 1) throughout the FMR1 locus were interrogated by (h)MeDIP-PCR in DNA extracted from four control (blue) and
eight FXS (red) patient PBMCs samples, data represent the mean of relative enrichment to input in log2 with standard deviation SD (left panels)
and individual data for the 2I3-4 locus (right panels). Significance levels of the mean difference in control and FXS PBMCs is indicated by triple
asterisks p≤ 0.001, double asterisks p≤ 0.01, single asterisk p ≤ 0.05, or no star, p > 0.05 using a t test with unequal variance (Additional file 11: Table
S4). The location of qPCR primer pairs (Additional file 9: Table S2) used in this study is illustrated. Data for inter-individual 5mC and 5hmC variation
across all selected FMR1 loci is available in Additional file 2: Figure S1 and Additional file 3: Figure S2. Arrows in a, b, and c illustrate observed anti-
correlation between 5mC and 5hmC enrichment in two FXS patients samples B and E. b (h)MedIP-array methylation profiles surrounding FMR1
transcriptional start site are represented in eight individual FXS patient samples (A to H in red) as compared to control samples (blue) for 5mC
and 5hmC. c Pyrosequencing at the FMR1 promoter region, using a commercial assay (HsFMR1, QIAGEN) located at proximity of the FMR1 start
site and a newly designed assay (B3) in a novel region of methylation changes located 738 bp downstream of the TSS confirm DNA methylation
enrichment at the base resolution level in all eight patients. The genomic location of measured CpGs relative to the TSS is indicated (see Add-
itional file 10: Table S3)
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may contribute to initiating and/or maintained FMR1
transcriptional silencing in FXS cells.
Combined 5mC, 5hmC, and histone PTM profiling
enhances the molecular and functional characterization of
FXS patient samples
We next investigated molecular relationship between
FMR1 transcriptional expression levels, DNA methyla-
tion and hydroxymethylation as well as individual
histones PTMs across the interrogated FMR1 loci in
PBMC FXS patient samples (Fig. 5a, Additional file 6:
Table S5). At the region surrounding the TSS (measured
with assays 3C1-2, 2I3-4, and 3C5-6, as well as by the
pyrosequencing assays HsFMR1 and B3), we found over-
all expected molecular interactions, characterizing 5mC
and H3K9me3 as repressive heterochromatic marks and
5hmC, H3K9me2, and H4K20me1 as marks associated
with an open euchromatic chromatin configuration and
Fig. 3 Broad, cell type-specific, epigenetic changes at the FMR1 locus in FXS cells. The graphs illustrate the relative enrichment (log2 fold enrichment)
of the indicated chromatin marks detected by ChIP (H3K27me3, H3K9me2 and -me3, H4K20me1 and -me3 H3K36me3, H3K4me2, H3K9ac, H4K16ac)
and (h)MeDIP (5mC and 5hmC) in FXS (red) and control (blue) fibroblasts. The upper panel illustrates the chromosomal and genomic location (region
covering 79 kb on ChrX: 146971000–147050000) as well as the indicated referenced Refseq genes: FMR1 and referenced antisense non coding RNAs
(FMR1AS1 and L29074.3). In the graphs, the thicker lines indicate higher deviation between biological replicates (FXS n = 3) (aggregation mean, sliding
window 529 bp). ChIP-PCR validation data is available Additional file 4: Figure S3
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clustering the eight patients in sub-groups of molecular
behavior at the TSS (Fig. 5a). Linear regression analyses
between FMR1 mRNA expression levels and 5mC/5hmC
MeDIP enrichment at the TSS confirms the functional
antagonism between these two DNA modifications at
least at the TSS (Fig. 5b, c). Interestingly, we did not
detect significant 5mC and 5hmC antagonism, at least
as measured by enrichment-based method, away from
the TSS regions of the FMR1 locus, which is consist-
ent with the limited observed changes in 5mC levels
outside of the FMR1 TSS by MeDIP-qPCR (Fig. 2a,
Additional file 2: Figure S1A). To further explore the
functional interactions between the different epigenetic
pathways at the different interrogated loci, we next ran
Fig. 4 Repressive epigenetic switch spanning entire FMR1 locus in FXS PBMCs. Relative ChIP-qPCR enrichment of the indicated chromatin histone
post-translational modifications (H3K4me2, H3K9me2, H3K9me3, and H4K20me1) in three control (blue) and eight (red) patients samples (A to H,
as in Fig. 2). Data represent the mean of relative enrichment to input in log2 with standard deviation SD (left panels). Significance levels of the
mean difference in control and FXS PBMCs is indicated by triple asterisks p≤ 0.001, double asterisks p≤ 0.01, single asterisk p≤ 0.05, or no star p > 0.05
using a t test with unequal variance (Additional file 11: Table S4). The bar graphs on the right hand-side represents individual patient data for
the indicated marks in region 2I3-4 located in the first intron of the FMR1 gene. The upper panel illustrates the FMR1 locus organization with
pyrosequencing (HsFMR1 and B3) as well as PCR assays locations (listed in Additional file 1: Table S1 and Additional file 9: Table S2)
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linear regression analyses using all available molecular
profiling data (Additional file 1: Table S1) providing a
matrix of linear correlation data (Additional file 6: Table
S5). This data confirms functional antagonism between
5mC and 5hmC at the TSS with a number of assays and
identifies novel potential cross-locus molecular correla-
tions between these two cytosine modifications. Investi-
gating the correlation between either 5mC or 5hmC and
all interrogated histone PTMs highlighted significant func-
tional correlations at heterologous FMR1 regions (illus-
trated Additional file 7: Figure S5). We speculate that
such interactions might reflect distant functional interac-
tions between epigenetic marks/pathways, a hypothesis
that will require further mechanistic investigations in lar-
ger cohorts and deployment of appropriate chromatin
configuration assays. No significant correlation between
histone PTM or 5mC/5hmC and the age of patients could
be found in this study (not shown). Overall, our data iden-
tifies novel potential regulatory interactions within the
broad FMR1 locus and demonstrate negative correlation
between 5mC and 5hmC at the TSS.
FMR1 methylation and hydroxymethylation are
significantly correlated with ABC scores in male FXS
patients
It was reported that the severity of FXS phenotypes can
be influenced by the FMR1 methylation status or the
magnitude of the FMRP deficit [2, 19]. We used linear
regression analyses to illustrate the relationship between
5mC (pyrosequencing at TSS and MeDIP-qPCR across
the FMR1 locus) and 5hmC (hMeDIP-qPCR) data to the
available Aberrant Behavioral Checklist—Community
Edition (ABC-C score) [39] for the eight clinical study
patient samples (Additional file 8: Table S6). Our ana-
lyses using TSS proximal quantitative assays (HsFMR1
and B3) confirm reported correlation between 5mC and
clinical severity (e.g., HsFMR1 vs ABC: Rsq 0.46 p value
0.0644—Fig. 6b, Additional file 8: Table S6). Interrogat-
ing all assays within regions I to V, we find region-
specific (anti)correlations between FMR1 methylation
and ABC scores (Fig. 6c), particularly significant in re-
gions III (Rsq 0.76 p value 0.005 for assay 3E8−9) and
region IV (Rsq 0.71 p value 0.008 for assay 3F3−4). Con-
sistent with significant levels of 5hmC changes and
inter-individual variability in measured 5hmC levels, we
observed a significant inverse correlation between 5hmC
and ABC-C scores for selected hMeDIP-PCR assays
(Fig. 6d) across most regions of FMR1 epigenetic
changes, particularly in regions II, III, and V. No signifi-
cant correlations were made with the histone PTMs data
(Additional file 8: Table S6). These data altogether con-
firm the utility of 5mC to predict FXS disease severity
and demonstrate that 5hmC measurements within the
FMR1 locus may be equally indicative of the disease
Fig. 5 FMR1 5hmC levels correlate with transcriptionally active chromatin and is reciprocal to 5mC levels at the FMR1 TSS. a Hierarchical
clustering using Ward’s method for the different indicated molecular endpoints at the region surrounding FMR1 TSS. Yellow color represents the
highest values, blue color the lowest, and the black the mean. b–c Linear regression analysis of indicated molecular assays (5mC, 5hmC, or FMR1
mRNA expression) in eight FXS patients PBMC samples. The coefficient of determination denoted RSq and the p value are indicated. The dots
gradient coloring represents the mRNA expression level for each sample, black for the highest expression level, and light grey for the lowest level.
All results from linear regression analyses are available from Additional file 6: Table S5
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severity. The combined measurement of 5mC and 5hmC
from single patient individuals may thus significantly en-
hance patient stratification.
Discussion
We report the identification of novel FMR1 regions of
chromatin and (hydroxy)-methylation (5mC and 5hmC)
perturbations associated with FMR1 epigenetic silencing
in FXS patient blood-derived (PBMC) samples. The gen-
omic regions of these epigenetic changes were consistent
across individual patient samples, strengthening their
functional relevance for FMR1 gene regulation. FMR1
locus-specific assays for selected epigenetic marks re-
vealed inter-individual quantitative differences in FXS
patients that may be related to FMR1 locus expression
and disease severity. We have integrated histone post-
translational modifications, DNA (hydroxy)-methylation,
FMR1 gene expression data, and clinical severity data to
identify new molecular and functional links between
molecular and clinical features. In particular, we have
established 5hmC and H4K20me1 as novel epigenetic
marks/pathways whose loss is associated with FMR1
epigenetic silencing in FXS cells, providing new opportun-
ities for enhanced molecular stratification of FXS patients
beyond the existing CGG repeat length and DNA methy-
lation assessments.
FMR1 locus regulation, beyond the transcription start site
region
While the region surrounding the FMR1 TSS (promoter/
CpG island and upstream part of the first intron) was pre-
viously reported to show epigenetic changes in FXS [21],
we report the identification of several new regions of epi-
genetic changes within and flanking the FMR1 coding re-
gion. The identification of epigenetic changes outside of
the FMR1 coding region suggests the presence of novel
structural or regulatory regions (e.g., enhancer) regulating
the expression of either FMR1 or non-coding RNA
Fig. 6 FMR1 5hmC levels anti-correlate with FXS patient disease severity. a FMR1 locus representation with indicated assay location (Additional file
9: Table S2 and Additional file 10: Table S3). b–d Linear regression analysis of indicated molecular assays (5mC vs 5hmC) and ABC-C clinical score
endpoints in eight FXS patients PBMC samples. The coefficient of determination denoted RSq and the p value are indicated. The dots gradient
coloring represents the mRNA expression level for each sample, black for the highest expression level, and light grey for the lowest level. Aberrant
Behavior Checklist (ABC-C) (sub)-scores (the higher, the more severe). All results from linear regression analyses are available from Additional file 8:
Table S6
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variants within the FMR1 locus, an observation that war-
rants further functional characterization. Among the
broad changes taking place in FMR1 gene body, three re-
gions are of particular interest. The region surrounding
the FMR1 TSS where DNA hypermethylation is accom-
panied by a heterochromatin switch with a decrease of the
active histones marks H3K4me2/H4K20me1 and an en-
richment of the repressive marks, mainly H3K9me3 and
H3K9me2. The 5′ part of the first intron of FMR1 is of
interest as it is characterized by a lower CpG density as
compared to the promoter and as previously reported by
Godler et al. [21]; it is likely participating to the suppres-
sion of FMR1 gene expression as a consequence of CGG
repeat expansion. The genomic region surrounding the
referenced FMR1AS antisense RNA TSS and the
alternative-splicing rich region located between introns 13
and 16 (reported to contribute the diversity of the FMR1
isoforms [40–42]) represent two additional sites of robust
epigenetic changes. Interestingly, both regions represent
sites of decreased 5mC levels, particularly evident from
fibroblast profiling data. Although it is known that the
methylation of DNA at the promoter suppresses gene ex-
pression, the role of DNA methylation in gene bodies is
unclear [43]. Recent data support a major role for intra-
genic methylation in regulating cell context-specific alter-
native promoters in gene bodies [38]. Hypermethylation
of FMR1 gene body in control fibroblasts may thus ensure
the integrity of the FMR1 mRNA transcript(s) and avoid
spurious transcription of this transcriptionally active locus.
In the absence of transcription in FXS fibroblast cells, the
normal regulation of FMR1 is perturbed and intragenic re-
gions not labeled for hypermethylation, accounting for dif-
ferential methylation in control and FXS fibroblasts.
Overall, FMR1 flanking and intragenic regions of differen-
tial methylation/chromatin structure highlight novel regu-
latory features of FMR1 regulation, providing new insights
into FMR1 gene regulation in normal, healthy control
cells.
Novel epigenetic pathways associated to FMR1 epigenetic
regulation
We report using hMeDIP-array/PCR that the pro-
moter/intron 1 region of active FMR1 is enriched in
5hmC. Previous bisulfite sequencing analyses of the
FMR1 promoter CpG island in normal individuals
have consistently reported largely unmethylated DNA
sequences spanning from the promoter region up to a
boundary region located at a site between 650 and 800
nucleotides upstream of the CGG repeat in the first
exon of the human FMR1 gene [44]. As bisulfite se-
quencing does not distinguish 5mC and 5hmC, we
propose that only selected cytosines may be hydroxy-
methylated within healthy control FMR1 promoter.
5hmC is catalyzed by the TET family of proteins [27]
suggesting a role for this pathway in the normal regu-
lation of FMR1. 5hmC is believed to both represent an
epigenetic mark of its own as well as contribute to ac-
tive DNA demethylation, possibly providing protection
against aberrant FMR1 promoter, CpG island and
CGG repeats methylation in healthy individuals (5-50
CGG repeats). MeCP2 was one of the first proteins
identified to bind to 5hmC [32]. While MeCP2 is trad-
itionally associated with gene repression through its
binding to 5mC and recruitment of a co-repressor
complex [45], it was shown to regulate gene activation
in the brain upon binding to 5hmC, an interaction lost
through MeCP2 point mutations in Rett syndrome pa-
tients [32, 45]. Differential 5hmC levels detected by
epigenomic profiling suggest a role for this mark in
the normal regulation of FMR1 gene expression in
healthy cells. Interestingly, changes in 5hmC were pre-
viously observed during cerebellum development at
genes regulated by the FMRP protein as well as at
many genes linked to autism [46], thus reinforcing the
importance of a TET-mediated 5hmC epigenetic path-
way in normal and pathological regulation of FMR1.
Histone H4 Lys 20 mono-methylation (H4K20me1) is
also affected in FXS cells. This epigenetic mark has been
implicated in the regulation of diverse processes ranging
from the DNA damage response, mitotic condensation,
and DNA replication to gene regulation. PR-Set7/Set8/
KMT5a is the sole enzyme that catalyzes H4K20me1
[47, 48]. Together, the identification of 5hmC and
H4K20me1 enrichment at FMR1 in normal individuals
highlights novel pathways whose deregulation upon
CGG repeat expansion might contribute to FMR1 silen-
cing and FXS physiopathology. The analyses presented
here were performed in FXS fibroblasts and PBMC sam-
ples, both representing surrogate tissues for this neuro-
logical disorder. PBMCs contain an array of different
blood cell types; the fibroblasts used in this study also
originate from different tissues and from patients of dif-
ferent ages, all representing potential confounding fac-
tors when investigating epigenetic differences at the
analyzed loci. An additional potential limitation relates
to the relatively small sample size in these analyses
(blood n = 4/8 controls/cases and fibroblasts n = 1/3 con-
trols/cases). We thus cannot formally exclude cell-type
and age-specific contributions to blood- and fibroblast-
derived chromatin profiling data and future validation of
key loci in sorted/purified cell populations from larger
cohorts of healthy volunteer, and patient samples may
be warranted to further explore the specificity of novel
DNA methylation markers for FXS. In addition, to better
understand the mechanisms associated to FMR1 silen-
cing in the target tissue and cells, it will also be import-
ant to investigate the epigenetic landscape of the FMR1
locus in healthy and FXS brain samples.
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Novel potential biomarkers for FXS diagnosis and drug
response
The methylation status of FMR1 promoter/upstream in-
tron 1 has been significantly correlated with the clinical
phenotype of FXS patients [5, 16–19]. We hypothesized
that additional epigenetic biomarkers within the FMR1
locus may enhance the development of novel clinical bio-
markers for FXS disease states as well as support the dis-
covery of novel mechanism-based therapeutic targets.
Whilst 5mC measurement at the FMR1 promoter can de-
tect full-mutated/hypermethylated FMR1 alleles in a mo-
saic cell population, we propose that the measurement of
5hmC (and other novel epigenetic features of FMR1 epi-
genetic activation) may help detect the unmethylated
(pre- and full-mutated) alleles within a mosaic population.
Conclusions
This in-depth analysis of the FMR1 locus epigenetic land-
scape in full-mutation FXS patient samples identifies un-
precedented regions of chromatin modifications that are
characteristic of a broad FMR1 repressive epigenetic switch.
Importantly, decreased levels of 5-hydroxymethylation
(5hmC), a recently rediscovered epigenetic mark, correlate
with FXS patient disease status. We propose that the com-
bined measurement of 5mC and 5hmC from single patient
individuals may provide novel diagnostic and therapeutic
opportunities for FXS syndrome.
Methods
Clinical specimens
For this study, purified PBMC samples from eight fragile X
patients were used. Subjects were male, aged 12–45 years
(inclusive), with a confirmed diagnosis of FXS based on
genetic sequencing results (full mutation, >200 CGG re-
peats). They were required to have a Clinical Global Im-
pressions of Severity (CGI-S) score of ≥4 (moderately ill)
and a score of ≥20 on the ABC-C scale (at screening). The
study protocol and all amendments were reviewed by the
Independent Ethics Committee for the study center. The
study was conducted according to the ethical principles of
the Declaration of Helsinki. Informed written consent was
obtained from each patient or parent/legal guardian before
randomization. PBMCs were purified from blood using
8 mL capacity PBMC separator tubes (BD Vacutainer CPT,
BD). Healthy control samples were obtained from Biorecla-
mation (n = 4, for hMeDIP) and from consented voluntary
donors (n = 3, for ChIP). GM05848 fibroblasts from a 4-
year-old fragile X patient, GM07072 fetal lung fibroblasts
from 22-week-old fetus with a fragile mutation, and
GM09497 fibroblasts from a 28-year-old fragile X patient,
from Coriell Institute for Medical Research were grown in
D-MEM supplemented with 15 % FBS, penicillin/strepto-
mycin, 2-mercaptoethanol (0.1 mM), and sodium pyruvate.
The ATCC BJ1 neonatal fibroblast cell line used as control
was cultured in the same condition.
FMR1 gene expression assays
FMR1 mRNA expression levels in the blood were mea-
sured by quantitative real-time polymerase chain reac-
tion (qRT-PCR); 500 ng of total RNA isolated from
the blood samples collected in PAXgene tubes was re-
verse transcribed to cDNA using random hexamers
and the high-capacity cDNA reverse transcription kit
with RNAse inhibitor according to the manufacturer’s
procedure (Applied Biosystems, Foster City, CA).
qPCR was performed using the ABI PRISM® 7900HT
Sequence Detection System (Applied Biosystem). The
following TaqMan assays obtained from Applied Bio-
systems were used: FMR1: Hs00924544_m1; actin B
(ACTB): Hs99999903_m1; beta-glucuronidase (GUSB):
Hs99999908_m1. All samples were processed in tripli-
cate with a 25-ng cDNA (total RNA equivalent) for
FMR1 and 10-ng cDNA (total RNA equivalent) for
reference gene assays (ACTB, GUSB). The qPCR con-
sisted of one step at 50 °C for 2 min, one denaturing
step at 95 °C for 10 min followed by 40 cycles of melting
(15 s at 95 °C), and annealing/extension (1 min at 60 °C).
To correct for any variation in mRNA content and en-
zymatic efficiencies, FMR1 gene expression levels were
normalized to the values of the most stable reference
genes, ACTB (actin beta) and GUSB (glucuronidase beta).
The data is presented as normalized relative quantity
(NRQ). A Cq (Ct) value >38 was considered to be the
background of the assay.
(Hydroxy)methylated DNA immunoprecipitation
Genomic DNA was prepared by overnight proteinase K
(pK) treatment in lysis buffer (10 mM Tris-HCl pH 8.0,
50 mM EDTA pH 8.0, 100 mM NaCl, 0.5 % SDS),
phenol-chloroform extraction, ethanol precipitation,
and RNaseA digestion. Genomic DNA was sonicated
(Bioruptor, Diagenode) to produce random fragments
ranging in size from 300 to 1000 bp and 2.5 μg of frag-
mented DNA was used for a standard hMeDIP assay.
DNA was denatured for 10 min at 95 °C and immuno-
precipitated for 3 h at 4 °C with 15 μl of monoclonal
antibody against 5-methylcytidine (BI-MECY-1000, Euro-
gentec) (MeDIP) or with 1 μl of a rabbit polyclonal
antibody against 5-hydroxymethylcytosine (#39769, active
Motif) (hMeDIP) in a final volume of 500 μl IP buffer
(10 mM sodium phosphate (pH 7.0), 140 mM NaCl,
0.05 % Triton X-100). The mixture was incubated with
40 μl magnetic beads (MeDIP: Dynabeads M-280 Sheep
anti-mouse IgG (Invitrogen) for 2 h at 4 °C/hMeDIP:
Dynabeads Protein G (#100.03D, Invitrogen) for 1 h
at 4 °C) and washed three times with 1 ml of IP buffer.
Beads were subsequently treated with proteinase K for 3 h
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at 50 °C and the methylated DNA recovered by phenol-
chloroform extraction followed by ethanol precipitation.
For microarray analysis, 50 ng of input DNA and 1/2
(h)MeDIP-enriched DNA was amplified using WGA2:
GenomePlex Complete Whole Genome Amplification kit
(Sigma). Amplified DNA was used for real-time qPCR
quantification and sent to Roche Nimblegen (Madison,
USA) for Cy3 and Cy5 labeling and hybridization on 12 ×
135 k NimbleGen custom arrays.
N-ChIP
Native chromatin immunoprecipitation (N-ChIP) protocol
was based on a published protocol [49] with some modifi-
cations. Aliquots of 5 million (10 million for Fibroblasts)
cells were thawed on ice and resuspended in 150 μl (250 μl
fibroblasts) of buffer 1 (0.3 M sucrose, 15 mM Tris
(pH 7.5), 60 mM KCl, 15 mM NaCl, 5 mM MgCl2,
0.1 mM EGTA); 150 μl (250 μl fibroblasts) of buffer 1 with
detergent (buffer1 including 0.5 mM DTT, 0.5 % Igepal,
and 1 % DOC) were added followed by an incubation
on ice for 10 min, and 300 μl (500 μl fibroblasts) of
MNase buffer (0.3 M Sucrose, 85 mM Tris, 3 mM
MgCl2, 2 mM CaCl2) containing 0.4 U MNase (0.64 U
fibroblasts) (Sigma) were added to each tube. Digestion
mixes were incubated at 28 °C using a thermomixer
(Eppendorf) for 8 min (20 min fibroblasts) shaking at
500 rpm. Digestion was stopped by adding EDTA to a
final concentration of 5 mM and tubes were left at room
temperature for 5 min. Non-soluble fractions were re-
moved by centrifugation at 18,000g for 10 min and collect-
ing the supernatant. The pellet was discarded; 5 to 10 μg
of chromatin was used for the immunoprecipitation with
each antibody: H3K4me2 (07-030, Millipore), H3K9me2
(39239, Active Motif), H3K9me3 (9754S, Cell Signaling),
H4K20me1 (39727, Active Motif), H4K20me3 (07-749,
Millipore), H3K36me3 (Ab5090), H3K9ac (07-352,
Millipore), H4K16ac (07-329, Millipore), and H3K27me3
(07-449, Millipore). The immunoprecipitation, washes,
and DNA purification were done with Magna ChIP™ A
Chromatin Immunoprecipitation Kit (Millipore #17-610)
following manufacturer’s protocol. For microarray ana-
lysis, input DNA and entire ChIP DNA was amplified
using WGA2: GenomePlex Complete Whole Genome
Amplification kit (Sigma) according to [50]. Amplified
DNA was used for real-time qPCR quantification and sent
to Roche Nimblegen (Madison, USA) for Cy3 and Cy5
labeling and hybridization on 12 × 135 k NimbleGen
custom arrays.
Real-time PCR
Real-time PCR was carried out using SYBR Green PCR
Master Mix (Applied Biosystems) and using an ABI
PRISM SDS 7900HT machine (Applied Biosystems).
Primers are listed in Additional file 9: Table S2.
FMR1 locus microarray design and data analyses
The custom Nimblegen array consists of 27,656 different
targeted (with known genomic location) 50-mer probes
and 30,039 random probes (no matches in the human hg19
genome); 4117 probes cover the broader FMR1 locus, a
247-kbp region encompassing FMR1 (chrX:146,993,469-
147,032,647), FMR1NB (chrX: 147,062,849-147,108,187),
and up to 100 kb of flanking genomic DNA sequence
(chrX: 146,911,760–147,159,387). The array design is avail-
able upon request. M values (log2 (IP-channel/input-chan-
nel)) were calculated per targeted probe and normalized for
each chip using Loess to account for non-linear dye bias.
Arrays of the same IP antibody were then normalized
across arrays by scaling to the same median absolute value.
Targeted probes are present four times on the array (with
different location), and these were summarized by aver-
aging after normalization. All pre-processing was per-
formed in the R-programming language; the limma
package of Bioconductor was used for normalization.
Pyrosequencing
Using the EZ DNA MethylationTM Kit (ZYMO Research),
200–300 ng of genomic DNA was bisulfite treated accord-
ing to the manufacturer’s protocol and eluted in 30 μl.
Pyrosequencing probes were designed with the Pyromark
Design 2.0 software package (QIAGEN). Primers for PCR
amplification and sequencing as well as the sequence cov-
ered by each assay are indicated in Additional file 10: Table
S3; 2 μl of converted DNA were used as input for PCR
amplification using the AmpliTaq Gold DNA Polymerase
(Applied Biosystems, N8080247), with one of two primers
biotinylated. The temperature profile of the cycles was
DNA polymerase activation at 95 °C for 15 min, de-
naturation at 95 °C for 30 s, annealing at 61 °C for 30 s,
and extension at 72 °C for 1 min for the first cycle. For
the next 19 cycles, the annealing temperature was de-
creased by 0.5 °C per cycle. Then, 36 cycles of amplifi-
cation were performed at 53 °C, the final annealing
temperature. The program was finished by a final
elongation step at 72 °C for 10 min. Biotinylated PCR
product were then purified and immobilized onto
streptavidin-coated Sepharose beads (GE Healthcare).
Pyrosequencing was performed on the PyroMark Q96
MD (QIAGEN) following the manufacturer’s instruc-
tions. Pyro QCpG 1.0.9 (QIAGEN) was used to quantify
DNA methylation at single CpGs.
Data integration and statistical analyses
Percentage of methylation per CpG obtained by pyrose-
quencing was summarized by averaging the value of all
CpGs per assay, 0 % being unmethylated and 100 % fully
methylated. 5hmC MeDIP and ChIP real-time PCR data
were first normalized using the efficacy of each qPCR
assay. The ratio IP/input was calculated as percent of
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input and values were log base 2 transformed (adding a
constant of 0.01 prior transformation) to meet the test as-
sumptions. Significance levels of the mean difference in
control and FXS PBMCs is indicated by “***” (p ≤ 0.001),
“**” (p ≤ 0.01), “*” (p ≤ 0.05), or no star (p > 0.05) using a t
test with unequal variance. The relationship between the
different molecular endpoints (5mC, 5hmC, histones
PTMs) to the clinical score (ABC-C score) [39] was
assessed via ordinary linear regression analysis (including
p value and R2 for goodness of fit).
Additional files
Additional file 1: Table S1. This table summarizes information for the
eight FXS patients with the clinical parameters (age, ABC-C score) and
molecular readouts (methylation status, number of repeats, (h)MeDIP-
qPCR data, ChIP-qPCR data). (XLSX 44 kb)
Additional file 2: Figure S1. Selected FMR1 genomic regions of
methylation change throughout the FMR1 locus (Fig. 2a, Additional file 1:
Table S1) were interrogated by MeDIP-qPCR (5mC) in DNA extracted from
four control (blue) and eight FXS (red) patient PBMCs samples (A). Data
represent the enrichment relative to input in individual samples. The loca-
tion of qPCR primer pairs used in this study is illustrated (B). (PDF 487 kb)
Additional file 3: Figure S2. Selected FMR1 genomic regions of
methylation change throughout the FMR1 locus (Fig. 2a, Additional file 1:
Table S1) were interrogated by hMeDIP-qPCR (5hmC) in DNA extracted
from four control (blue) and eight FXS (red) patient PBMCs samples (A).
Data represent the enrichment relative to input in individual samples.
The location of qPCR primer pairs used in this study is illustrated (B). (PDF
497 kb)
Additional file 4: Figure S3. Selected FMR1 and unrelated loci (APRT
and OCT4) were interrogated by ChIP-PCR in healthy and FXS fibroblasts,
validating Fig. 3 FMR1 microarray results. Data represent the enrichment
relative to input in individual samples. (PDF 519 kb)
Additional file 5: Figure S4. Selected unrelated loci were interrogated
by ChIP-qPCR to validate the specificity of changes observed at FMR1 in
FXS patient cells. No significant change in H3K4me2, H4K20me1,
H3K9me2, and me3 were observed at three selected loci (active locus
RPL19 and two developmentally regulated loci Cdx2 and Oct4). (PDF
409 kb)
Additional file 6: Table S5. This table summarizes linear regression
analyses (p value, RSq, R) for the indicated molecular assay (5mC, 5hmC,
histone PTMs). (XLSX 128 kb)
Additional file 7: Figure S5. Linear regression analysis of the methylation
(5mC) or hydroxymethylation (5hmC) assays and the different histones marks
(H3K4me2, H3K9me2, H3K9me3, H4K20me1) in eight FXS patients PBMC
samples. Graphs show the relationship with the highest coefficient of
determination denoted RSq. The p value is indicated, and the dots gradient
coloring represents the mRNA expression level for each sample, black for the
highest expression level, and light grey for the lowest level. (PDF 547 kb)
Additional file 8: Table S6. This table summarizes the results of linear
regression analyses and the Spearman correlation (p value, RSq, R)
looking at the relationship between the ABC-C score and the indicated
epigenetic readouts (5mC, 5hmC, histone PTMs). (XLSX 16 kb)
Additional file 9: Table S2. List of the real-time qPCR assays. This table
indicates the primers sequence as well as chromosome coordinates of
amplicon analyzed by real-time qPCR. (DOC 37 kb)
Additional file 10: Table S3. List of pyrosequencing assays. This table
indicates the primers sequence as well as chromosome coordinates of
the amplicon analyzed by pyrosequencing. (DOC 28 kb)
Additional file 11: Table S4. This table summarizes the values from the
statistical analyses (mean, SD, SEM, p value) for each sample groups
(control and FXS) for each epigenetic readout (5mC, 5hmC, histone PTMs).
(XLSX 15 kb)
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